Background. In Vietnam, the Mycobacterium tuberculosis Beijing genotype is associated with multi-drug resistance and is emerging. A possible explanation for this genotype's success is an increased rate of relapse.
Despite extensive control efforts, tuberculosis remains a major public health problem, with an estimated 8.8 million cases and almost 1.4 million deaths per year worldwide [1] . On the basis of several techniques [2] , molecular epidemiological studies have identified genotype families of Mycobacterium tuberculosis, including the Beijing genotype, which is among the predominant genotypes in East and Southeast Asia [3] [4] [5] [6] . The Beijing genotype has gained particular attention because of its association with multidrugresistant tuberculosis (MDR-TB), both in outbreaks and in a number of population-based studies [7] [8] [9] [10] [11] . In addition, its association with young adult age in several settings suggests that the Beijing genotype is emerging [3, 9, 10] . The cause and consequence of this possible shift in the population structure of M. tuberculosis have not been studied sufficiently. Although Beijing genotype strains have shown increased virulence in animal studies, data on altered pathogenesis in humans have remained inconclusive [4] . While one study from Indonesia found increased rates of treatment failure in cases caused by Beijing strains [12] , other studies did not [13] [14] [15] [16] . Reports of increased relapse rates with Beijing strains have been more consistent [14, 17, 18] , although their study designs (casecontrol and/or passive follow-up) allow for alternative interpretations.
In Vietnam, the Beijing genotype is highly prevalent, causing about 40% of tuberculosis cases [3, 10] , and is associated with resistance to streptomycin and isoniazid [3] , as well as with MDR-tuberculosis [10] , providing an ideal environment to study epidemiological phenomena associated with Beijing genotype infections. For treatment of previously untreated tuberculosis patients (new cases), the Vietnamese National Tuberculosis Program uses an 8-month regimen, with isoniazid, rifampicin, streptomycin, and pyrazinamide administered for 2 months, followed by isoniazid and ethambutol for 6 months (ie, the 2HRSZ/6HE regimen). Although reported failure rates with this regimen are low (eg, 1.7% in the south of Vietnam in 2010 [unpublished data]), there is concern about its potential role in the development of MDR-tuberculosis [5] . A study in Ho Chi Minh City found that 15 of 23 patients (65%) who did not respond to 2HRSZ/ 6HE treatment had acquired MDR-tuberculosis during treatment [11] . Also, the rate of recurrent tuberculosis in Vietnam is high, as is the proportion of tuberculosis patients with a history of cured tuberculosis (13.3% in the south of the country [unpublished data]). This high relapse rate may be due to use of ethambutol instead of rifampicin in the continuation phase [19] , but it may also be associated with the high prevalence of the Beijing genotype among M. tuberculosis isolates from previously treated patients in this country [10, 17] .
We studied the association between culture-proven treatment relapse and the Beijing genotype in a prospective cohort study among patients in Vietnam with smear-positive pulmonary tuberculosis who were initially cured by first-line treatment.
METHODS

Recruitment of Patients and Study Design
This prospective cohort study was performed in 3 adjacent rural districts in the Mekong River Delta in southern Vietnam. Nested in a population-based study of tuberculosis cases spanning 4 years, the cohort included all patients consecutively diagnosed and registered for treatment from 1 July 2005 through 30 June 2007. Details of the study site and procedures have been described elsewhere [10, 16] .
In brief, all patients in the study area aged ≥15 years and with a diagnosis of smear-positive pulmonary tuberculosis were eligible for enrollment and provided 2 sputum specimens for smear examination and M. tuberculosis culture before treatment. Enrolled patients were followed up during standard first-line treatment, with sputum smear microscopy and culture performed at the end of treatment (after 8 months). Patients whose sputum smear and culture were negative for M. tuberculosis were visited by study staff twice, at around 9 and 18 months after treatment completion. In addition, data were collected if, during these 18 months, patients reported with symptoms at any of the participating tuberculosis clinics. Patients who had any symptom suggesting recurrent tuberculosis during these visits or who themselves consulted a participating clinic provided 2 sputum specimens for smear and culture. Data were also collected from clinic reports, death certificates, and interviews with family members, to determine any intermediate tuberculosis treatment received elsewhere and causes of death among the study patients.
Ethical clearance was obtained from the ethical health committee of the Ho Chi Minh City Council. All included patients provided written informed consent.
Laboratory Procedures
Sputum specimens were kept refrigerated and transported to Pham Ngoc Thach Hospital in Ho Chi Minh City within 72 hours after collection. Specimens were decontaminated and liquefied with 1% N-acetylcystine and 2% NaOH, inoculated on modified Ogawa medium, and incubated at 37°C. Cultures were examined for growth after 1, 2, 4, 6, and 8 weeks of incubation. Results of cultures with no growth after 8 weeks were reported as negative. M. tuberculosis was identified using the niacin and nitrate tests [20] . Drug susceptibility testing was performed by the proportion method [21] . Criteria for drug resistance were growth of ≥1% of the colony-forming units at 28 or 42 days, compared with the drug-free control medium, at the following drug concentrations: isoniazid 0.2 μg/mL, rifampicin 40 μg/mL, streptomycin 4 μg/mL, and ethambutol 2 μg/mL. MDR-tuberculosis was defined as resistance to both rifampicin and isoniazid. Pretreatment drug resistance testing was performed at a later stage on stored isolates, and results were not used for patient management, in accordance with Vietnamese National Tuberculosis Program guidelines prevailing at the time of the study.
Genomic DNA was extracted from M. tuberculosis-positive cultures by using a previously described method [22] . Spoligotyping was performed according to internationally standardized methods [23] . Variable number of tandem repeats (VNTR) typing was done using 15 loci, as described by Supply et al [24] .
Definitions
We defined the cohort for the present analyses as all patients who were sputum smear-and culture-negative at the end of treatment, and we defined follow-up time as the period between the date of completion of treatment and the date of the 18-month visit, a bacteriological diagnosis of recurrent tuberculosis, or the patient's death, whichever came first. Recurrent tuberculosis was defined as any case in this cohort of culture-positive tuberculosis observed during the follow-up period. Unfavorable treatment outcomes were defined as recurrent tuberculosis or death during the follow-up period. Recurrent tuberculosis was considered to be due to M. tuberculosis reinfection if the pretreatment and follow-up isolates had different spoligotypes or VNTR types that differed by ≥2 loci. We defined relapse as recurrent tuberculosis caused by the same strain, with strain identity confirmed by detection of identical spoligotypes and identical VNTR profiles in pretreatment and follow-up isolates or by detection of identical spoligotypes and VNTR types that differed by no more than a single locus [24] . The Beijing genotype was defined by spoligotyping as any isolate without direct-repeat spacers 1-34 and the presence of 3 of the spacers 35-43 [25] . Other genotypes were defined as described by Brudey et al [2] .
Data Analysis
Data were double entered in EpiInfo v6.04 (Centers for Disease Control and Prevention, Atlanta, GA); discrepancies were corrected on the basis of the raw data. Analyses were performed in Stata v10SE (StataCorp, College Station, TX).
For significance testing on comparisons of categorical variables, the χ 2 test or the 2-sided Fisher exact test was used as appropriate. Associations between genotype and outcome were assessed by survival analysis using the log-rank test. We based our primary analysis on relapse as the outcome; patients with M. tuberculosis reinfection were censored in this analysis. We considered genotype, categorized as Beijing genotype versus all other genotypes, as our explanatory variable of interest and considered age, sex, tuberculosis treatment, and tuberculosis drug resistance as potential confounders. In similar secondary analyses, we took recurrent tuberculosis and unfavorable treatment as separate outcomes. Multivariable analyses were done by Cox proportional hazard modeling. P values for contribution to multivariate models, including interaction, were based on the likelihood ratio test. All tests were done at the 5% significance level.
RESULTS
Of 1331 patients enrolled in the treatment cohort, 1073 were smear and culture negative at the end of treatment and included for follow-up in the present study. Detailed characteristics of these patients are shown in Table 1 . We excluded 5 patients for loss to follow-up directly following the end of treatment ( Figure 1 ). Of the 1068 patients available for analysis, 984 (92.1%) initially had new tuberculosis, and 84 (7.9%) had been previously treated; 816 (76.4%) were male, and 252 (23.6%) were female. Pretreatment isolates from 357 patients (33.4%) belonged to the Beijing genotype, and those from 711 patients (66.6%) belonged to other genotypes. Among these other genotypes, the most prevalent was the East African Table 2 ). The follow-up period ranged from 2.1 to 28.1 months (some patients who were not found at the 18-month visit were visited again at a later point in time), with a mean of 18.4 months. There were 20 deaths during follow-up: 1 due to tuberculosis, 2 due to accidents, and 17 due to other causes. For 1 patient, no death certificate was available. Symptoms requiring collection of sputum at any time during follow-up were reported by 198 patients (18.5%). Of these, sputum samples were obtained for 185 patients, and valid culture results were available for 181 (97.8%). Culture results were positive at any time point for 35 of 181 patients (19.3%). Of these 35 cases of recurrent tuberculosis, 12 were due to reinfection with a different strain. The 12 reinfection strains differed from the pretreatment strains by different spoligotype and VNTR type, for 3 patients, and by different VNTR type, for 9.
Relapse
Relapse with the same strain was thus recorded in 23 patients (incidence rate, 1.39 cases/100 person-years of follow-up). Of these, 17 patients (73.1%) had Beijing genotype infections, compared with 340 of 1045 (32.5%) with no relapse (P < .001). Survival analysis also showed a significantly higher relapse rate for patients with Beijing genotype infections than for patients with other genotype infections (P < .001; Figure 2) . In univariate analysis, relapse was significantly associated with the Beijing genotype (hazard ratio [HR], 5.90 vs non-Beijing; P < .001), as well as with resistance to streptomycin (HR, 3.19; P = .006) or isoniazid (HR, 5.81; P < .001). There was no (Table 2 ).There were no significant interactions for the association with relapse between genotype and drug resistance or treatment history. For the multivariate Cox regression model, the overall departure from the proportional hazards assumption was nonsignificant (P = .487), whereas this departure was almost significant (P = .051) for genotype. Inspection of the log-log transformed survival curves suggested convergence after 18 months of follow-up, when 1 relapse case among Beijing infections and 2 relapse cases among non-Beijing infections occurred, for equal incidence rates of 3.24 cases/100 (95% CI, <.1 to 15.2) and 3.24 cases/100 person-years (95% CI, .3-9.6), respectively. We therefore repeated the Cox model for the first 18 months of observation only, which showed a similar pattern of associations, with significant HRs for Beijing genotype (adjusted HR, 7.40; 95% CI, 2.36-23.22; P < .001) and isoniazid resistance (adjusted HR, 4.73; 95% CI, 1.58-14.20; P = .006).
Recurrent Tuberculosis and Unfavorable Outcomes
We may have misclassified relapse cases as reinfections or as deaths. Therefore, in secondary analyses we assessed the associations between genotype and recurrent tuberculosis and between genotype and unfavorable outcomes (ie, recurrent tuberculosis or death). Of 35 of 1068 (3.3%) patients who had recurrent tuberculosis, 27 (77.1%) had Beijing genotype infections before start of treatment (difference with no recurrence, P < .001). The pattern of univariate and multivariate associations for recurrent tuberculosis was similar to that for relapse ( 
Intervals
There were no significant differences in interval between cure and reinfection or recurrent tuberculosis between Beijing and non-Beijing genotypes (19.8 vs 21.3 months and 13.9 vs 17.2 months, respectively; P > .05 for each comparison). However, the average time from cure to relapse was shorter in patients infected with Beijing genotype strains than in patients infected with other strains (10.5 vs 15.8 months; P = .031; Table 4 ).
Drug Resistance Amplification
Among the 21 relapse cases that had non-MDR isolates before treatment, amplification of drug resistance occurred in 4 of 15 patients (26.7%) infected by Beijing genotype strains, compared with 0 of 6 patients infected with other strains (P = .429). Of the 4 cases involving non-MDR Beijing genotype strains in which amplification occurred, 3 had become MDR, with 1 initially monoresistant to isoniazid and 2 initially resistant to both isoniazid and streptomycin.
DISCUSSION
We observed that patients infected by Beijing genotype strains had a 5.48-fold increased risk of relapse as compared to patients infected with other genotypes. This association was independent of tuberculosis treatment history and pretreatment drug resistance pattern and was robust to possible misclassification of relapse cases as reinfections and of missed relapse cases due to death. It confirms earlier observations from Vietnam [17] and Singapore [18] , as well as from a multicountry clinical trial [14] , which each had limitations due to casecontrol design, passive follow-up, and/or marginal statistical significance of the observed difference. The relative risk of relapse for Beijing versus non-Beijing strains was larger in our study (5.48) than in the multicountry trial in which patients were also followed actively for recurrent tuberculosis (2.2) Figure 2 . Survival curve for tuberculosis relapse among 1068 patients followed up after cure with first-line tuberculosis treatment in Vietnam, by genotype (other vs Beijing). P < .001, by the log-rank test, for differences between genotypes. [14] . This difference may reflect the overall higher relapse rate in Vietnam that is likely associated with the use of the 8-month 2HRSZ/6HE regimen for new patients [19] . It also suggests that the effect of Beijing genotype on relapse rates may be stronger with the 8-month regimen than with the 6-month regimen, which includes a 4-month continuation phase of isoniazid-rifampicin. Furthermore, relapse in our study was significantly associated with resistance to isoniazid but not with resistance to streptomycin or MDR, probably reflecting the use of isoniazid-ethambutol in the continuation phase of treatment.
There are a number of possible explanations for the increased relapse rate in tuberculosis cases caused by Beijing genotype infections. Higher relapse rates may in fact reflect increased failure rates for Beijing genotype infections but with very low bacterial loads, resulting in negative culture results at the end of treatment. Once drug treatment is stopped these remaining bacilli start replicating again, causing symptoms and yielding positive culture results within months. This may explain why we observed shorter intervals between cure and relapse in cases caused by Beijing strains. However, our earlier study found no association between genotype and treatment failure [16] , and no other study clearly did so, except for one from Indonesia [4, 12] . Alternatively, increased relapse rates may reflect increased rates of progression from latent infection to disease. In this hypothesis residual bacilli that during tuberculosis treatment become contained in granulomas, as they are during latent infection, reactivate, and Beijing bacilli do so more efficiently than other genotype bacilli. Indeed, a study from Gambia, although based on low numbers of cases, suggested that Beijing strains have higher rates of progression from latent infection to disease [26] . The observed association of the Beijing genotype and relapse is probably due to a combination of factors. In animal models, Beijing strain bacilli escape from immune responses more efficiently than other genotype bacilli [27, 28] . Moreover, they grow more rapidly in human macrophages [29] , which may provide them with a higher potential for progressing from latent infection to disease than other strains.
Note that our findings do not imply that the overall proportion of Beijing strain infections that progress to disease is increased as compared to other genotype infections. In fact, they suggest that the relapse rate for cases caused by Beijing strains is only increased during the first 18 months following cure, which would translate into a lower average incubation period rather than into a higher cumulative incidence of disease progression.
The observed increased relapse rate for Beijing strain infections was independent of (multi)drug resistance. The strong association in this site [10, 16] and elsewhere [30, 31] between Beijing genotype and MDR-tuberculosis implies that these increased relapse rates also result in increased spread of MDRtuberculosis. Moreover, although differences were not significant, amplification to MDR-tuberculosis was observed for Beijing strains but not for other genotype strains in the present study. A potential explanation is provided by recent in vitro and mouse model data suggesting that Beijing bacteria, in comparison to the also prevalent East African Indian bacteria, have a higher intrinsic resistance to treatment by rifampicin, as well as a higher mutation frequency regarding the generation of rifampicin-resistant mutants [32] . It would be interesting to subject Beijing genotype isolates that caused relapses after curative treatment to mutation analysis in a fluctuation assay [32] .
A higher rate of early relapse for tuberculosis cases caused by Beijing strains may explain several epidemiological observations that have thus far remained elusive. First, it would explain why, in Vietnam, the proportion of tuberculosis cases due to Beijing genotype infections seems to increase [3, 10] and why the Beijing genotype infections are more common in patients with a history of tuberculosis treatment than in new cases [10] . For Vietnam, an increased relapse rate for Beijing strains seems reason to replace the 8-month regimen by the internationally recommended 6-month regimen. Second, increased early relapse rates and/or shorter incubation periods for Beijing strains would predict that these strains have a selective advantage under conditions of very high transmission rates. This selective advantage may explain the high prevalence of Beijing strain infections in prisons, its association with history of imprisonment in former Soviet Union countries, and, in combination with a higher rate of acquisition/ amplification of drug resistance, the rapid spread of MDR-tuberculosis caused by Beijing strains in these settings [8, 9] .
There are potential limitations to our study. Human immunodeficiency virus (HIV) testing was not routinely performed for all patients. However, although situational data on HIV prevalence were not available, the HIV infection prevalence in Vietnam is estimated to be 0.4% of the adult population, with a substantially lower prevalence in rural provinces than in major cities [33] . Furthermore, HIV infection is not known to affect the risk of tuberculosis relapse. A recent study from Malawi showed HIV infection to be associated with an increased rate of M. tuberculosis reinfection but not with an increased rate of relapse, despite the use, as in Vietnam, of an 8-month first-line regimen that included rifampicin for the first 2 months only [34] . We did not collect data on the extent of radiographic abnormalities in our study patients, and some studies have suggested an association between Beijing genotype infection and pretreatment cavitation, a known risk [4] . However, the majority of published studies on this subject showed no such associations, and those that did suggest increased prevalence of cavitation among Beijing strains had no non-Beijing control group [35] , found differences in radiographic patterns but not specifically for cavitation [36] , or found no association after multivariate adjustment for confounding [9] . Therefore, we believe that the extent of pulmonary cavitation is an unlikely confounder for the association between genotype and relapse rate in our study. The follow-up time for recurrence was, on average, 18 months, which may be too short to pick up all cases of tuberculosis relapse, and indeed our analyses suggested that the observed difference in relapse rates relates to this early phase only. Therefore, our findings cannot be extrapolated to longer periods following cure. However, it is known that the recurrence of tuberculosis is highest in the first 2 years after treatment, after which it gradually decreases [37, 38] In summary, our study revealed that Beijing genotype infection is a strong and independent risk factor for relapse after first-line treatment. This may explain, at least in part, the emergence of tuberculosis due to Beijing genotype infections in Vietnam and elsewhere.
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